…) (IDDF2026-ABS-0455 Figure 1. The effectiveness of WMT on core ADHD symptoms in all children; IDDF2026-ABS-0455 Figure 2. The effec…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 49 of 2459…nce in non-responsive (NRCD), refractory (RCD), and complicated coeliac disease (CCD) has not been systematically evaluated. Current guidelines…
…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…
…ntenance therapy in patients with moderately to severely active Crohn’s disease (CD) in the ongoing U-ENDURE LTE study.Methods Patients who com…
…ate search for infection and sepsis rather than trigger empiric HF treatment alone. NT-proBNP should not be interpreted in isolati…
…nts with CAC substantially improved clinician documentation and statin prescription rates. While larger studies should assess durabili…
…Introduction Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy,…
…9%/3.0% and 2.0%/3.9%/0% of patients receiving fipaxalparant QD/fipaxalparant BID/placebo, respectively. No patients met Hy’s law.Conclusions…
…0.042) groups. After 12 months, the proportion of patients with HIV RNA <50 copies/mL was comparable in all groups: 90% (36/40) in …
…gents were (dabigatran and warfarin) and were not (apixaban and rivaroxaban) available.Methods We included patients with anticoagulation-re…